Kate Amato Foundation Awarded Projects
Harnessing Therapeutic Probiotics to Enhance CAR-T Cell Activity in Pediatric Solid Tumors
Project Goal: This project will explore how bacteria, CAR-T cells, and the immune system interact inside tumors, laying the groundwork for a smarter, more cooperative therapy that could one day offer new hope to children with difficult-to-target cancers.
Institution: Baylor College of Medicine
Researchers: Rosa Vincent, PhD
Year Awarded: 2025
Type of Childhood Cancer: Neuroblastoma and Osteosarcoma
Project Description:
Cancer treatment is quickly evolving from traditional chemotherapy to engineering our own cells as living medicines. With this momentum, I am developing a new kind of cell therapy that brings together two unlikely partners: CAR-T cells – designer immune cells that target specific markers on cancer cells, and probiotics – ‘helpful bacteria’ – that can selectively grow in solid tumors. CAR-T cells have cured children with certain blood cancers, but they’ve struggled in solid tumors like neuroblastoma and osteosarcoma where the hostile tumor environment, combined with the lack of ‘good’ markers to target, often shuts them down before they have a chance to work. Remarkably, the same harsh environment that weakens T cells can fuel the growth of some probiotic bacteria. These bacteria can be easily engineered to deliver custom-made signals and therapies right where they’re needed most: inside the tumor. In my earlier work, I engineered bacteria to “paint” tumors with synthetic markers, making them easier for CAR-T cells to target and destroy. This worked – at first. But overtime, too much additional stimulation from the bacteria eventually caused the CAR-T cells to burn out. To fix this, I’m redesigning the bacterial cell surface to be gentler on the immune system, making these microbes better partners for CAR-T cells and safer for young patients. My work will explore how bacteria, CAR-T cells, and the immune system interact inside tumors – laying the groundwork for a smarter, more cooperative therapy that could one day offer new hope to children with difficult-to-target cancers.